Tirzepatide
A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and obesity that achieves greater weight loss than GLP-1 agonists alone.
Also known as: Mounjaro, Zepbound, LY3298176
Regulatory Status
Classification date: 2022-05-13
Compounding: Not currently available for compounding
Evidence Summary
How It Works
Tirzepatide is a novel dual incretin agonist that activates both GIP and GLP-1 receptors, the two primary gut hormones responsible for post-meal insulin secretion. The GIP component enhances fat metabolism and may improve the tolerability of GLP-1-mediated appetite suppression. In head-to-head trials, tirzepatide produced up to 22.5% mean body weight reduction, exceeding semaglutide, and delivered superior HbA1c lowering in patients with type 2 diabetes.
Common Applications
Safety & Considerations
Side effect profile similar to GLP-1 agonists: nausea, diarrhea, vomiting, and constipation are most common and generally transient with dose escalation. Same boxed warning as semaglutide for thyroid C-cell tumors in rodents. Contraindicated in patients with MEN2 or personal/family history of medullary thyroid carcinoma. Monitor for pancreatitis, gallbladder events, and hypoglycemia when combined with insulin or sulfonylureas.
An independent licensed telehealth network prescribes this compound, and a licensed provider in that network decides whether it is appropriate for you.
Explore the LEAN program →Regulatory classifications can change rapidly. The information shown here was last verified on 2022-05-13. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.